U.S. FDA issues 4 observations to Biocon API facility in Bengaluru

An energetic pharmaceutical ingredient (API) facility of Biocon in Bengaluru has been issued 4 observations by the U.S. Meals and Drug Administration put up an inspection.

“The U.S. FDA carried out a surveillance inspection of our API facility (Web site 2) positioned in Bengaluru from September 23-27. 4 observations have been cited on the finish of the inspection, which the corporate can be addressing throughout the stipulated time. The corporate doesn’t foresee any influence on the enterprise,” Biocon mentioned in a submitting on Saturday.